PBMs are Clear as Mud: The Value of a Fee-Based, Transparent Model
Transparency in the drug supply chain is desperately needed to deliver consumers the lowest cost and highest value prescription drugs.
Tag: prescription drugs / drug prices
ACHP Statement on the Announcement of the First Ten Drugs to be Negotiated in the IRA
As the only national payer organization that supported robust drug pricing reform, including allowing direct government negotiation for drugs without competition, we are pleased by the White House’s announcement of the first ten drugs to be negotiated.
ACHP Statement on Senate Finance Committee PBM Markup
ACHP commends Senate Finance Committee Chairman Ron Wyden (D-OR) and Ranking Member Mike Crapo (R-ID) for their leadership to reform PBMs. ACHP supports the Committee’s bipartisan efforts to increase PBM transparency, as well as modernize the industry’s revenue models.
ACHP Reaffirms Support for Comprehensive Drug Pricing Reform
ACHP is the only national payer group pushing for comprehensive drug pricing reform. Allowing Medicare to negotiate for lower prescription drug prices is an important step toward better health care for all.
ACHP Comments on USPTO’s Patent Rights Initiatives
ACHP submitted a comment letter to USPTO with recommendations to ensure reliability of patent rights and address the high cost of drugs.
